This is consistent with the protumourigenic role of SIRT1 in inducing EMT in pancreatic cancer, hepatocellular carcinoma and gastric cancer, but discordant with its EMT inhibition in breast cancer, lung cancer and ovarian cancer [39–44]. This evidence concerns the gene SIRT1 and ovarian carcinoma.